Stock Events

Stock Events

NLS Pharmaceutics 

$0.76
48
+$0.02+2.97% Thursday 20:00

Statistics

Day High
0.83
Day Low
0.76
52W High
41.5
52W Low
0.76
Volume
30,337,583
Avg. Volume
76,152
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q1 2024
Q3 2025
Q4 2025
-84
-83.67
-83.33
-83
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2017
2018
2019
0Revenue
-2.72MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NLSP. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap8.35B
Jazz Pharmaceuticals competes directly with NLS Pharmaceutics in the narcolepsy treatment market, offering Xyrem and Xywav, leading treatments for cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients.
Takeda Pharmaceutical
TAK
Mkt Cap42.62B
Takeda Pharmaceutical Company offers Wakix (pitolisant), which competes in the narcolepsy treatment market, particularly targeting excessive daytime sleepiness, a key area for NLS Pharmaceutics.
Heron Therapeutics
HRTX
Mkt Cap212.64M
Heron Therapeutics, with its focus on CNS disorders including treatments for postoperative pain, indirectly competes with NLS Pharmaceutics by targeting overlapping areas in the central nervous system disorder treatment market.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries offers several CNS disorder treatments, including generic versions of modafinil and armodafinil for narcolepsy, directly competing with NLS Pharmaceutics' focus on narcolepsy and sleep disorders.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes in the broader CNS disorder space, including multiple sclerosis and Alzheimer's, which overlaps with NLS Pharmaceutics' focus on central nervous system disorders, albeit in different therapeutic areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
ACADIA Pharmaceuticals, with its focus on CNS disorders such as Parkinson’s disease psychosis, competes in the broader market for neurological treatments, indirectly competing with NLS Pharmaceutics.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes competes in the CNS therapeutic area with treatments for schizophrenia, bipolar I disorder, and depression, indirectly competing with NLS Pharmaceutics by targeting the broader CNS disorder market.
Neurocrine Biosciences
NBIX
Mkt Cap14.28B
Neurocrine Biosciences focuses on neurological and endocrine diseases, including treatments for tardive dyskinesia and Parkinson’s disease, placing it in indirect competition with NLS Pharmaceutics in the CNS disorder space.

About

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
Show more...
CEO
Mr. Alexander Zwyer M.B.A.
Employees
6
Country
CH

Listings

XNAS
US
NCEL
BOATS
BOATS
NCEL.BOATS

0 Comments

Share your thoughts

FAQ

What is NLS Pharmaceutics stock price today?▼
The current price of NLSP is $0.76 USD — it has increased by +2.97% in the past 24 hours. Watch NLS Pharmaceutics stock price performance more closely on the chart.
What is NLS Pharmaceutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NLS Pharmaceutics stocks are traded under the ticker NLSP.
Is NLS Pharmaceutics stock price growing?▼
NLSP stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year NLS Pharmaceutics has showed a -48.86% decrease.
When is the next NLS Pharmaceutics earnings date?▼
NLS Pharmaceutics is going to release the next earnings report on September 02, 2026.
What is NLS Pharmaceutics revenue for the last year?▼
NLS Pharmaceutics revenue for the last year amounts to 0 USD.
What is NLS Pharmaceutics net income for the last year?▼
NLSP net income for the last year is -2.72M USD.
How many employees does NLS Pharmaceutics have?▼
As of April 02, 2026, the company has 6 employees.
In which sector is NLS Pharmaceutics located?▼
NLS Pharmaceutics operates in the Health Care sector.
When did NLS Pharmaceutics complete a stock split?▼
The last stock split for NLS Pharmaceutics was on October 31, 2025 with a ratio of 1:10.
Where is NLS Pharmaceutics headquartered?▼
NLS Pharmaceutics is headquartered in Zurich, CH.